You are here

P&T News

January 25

Underserved patients haven’t benefitted, researchers conclude
Solanezumab did not significantly slow cognitive decline
Agencies send warning letters to 15 companies over alleged “scams”
FDA adds a second indication for the medication

January 23

Use of rescue medications also falls in LIBERTY study
After five years, about half of recipients held onto cardiovascular benefits
Most fatalities involved children who didn’t get flu shots
Report from National Academies reaches mixed conclusions
These and other companies are taking steps to fight antimicrobial resistance

January 22

Eosinophilic asthma drug is currently given based on weight
Under-users tended to be smaller, nonurban, and Western practices
Complete response letter seeks more information on CAM2038
ASP0113 missed key endpoints in phase 3 trial

January 19

32 states experience high activity levels in week ending January 13

January 18

Overall survival rose by about one-third in a European study
Risk of death drops 21% in relapsed or refractory patients
Prostate cancer drug earns $1 billion a year for Janssen
Median PFS more than doubles in CELESTIAL trial
Health systems’ plan is a response to shortages and price hikes

January 16

New label includes data on three additional EGFR mutations: L861Q, G719X, and S768I

Pages